TCGA-CR-6478-01A-11R-1873-07
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 0.041780822
- sex
- female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.610
- ALLOGRAFT_REJECTION+0.590
- INTERFERON_GAMMA_RESPONSE+0.560
- IL6_JAK_STAT3_SIGNALING+0.500
- INFLAMMATORY_RESPONSE+0.490
- COMPLEMENT+0.430
- E2F_TARGETS+0.410
- MYC_TARGETS_V2+0.340
- G2M_CHECKPOINT+0.320
- IL2_STAT5_SIGNALING+0.300
Top 10 suppressed
- MYOGENESIS-0.380
- TGF_BETA_SIGNALING-0.250
- OXIDATIVE_PHOSPHORYLATION-0.230
- P53_PATHWAY-0.230
- PEROXISOME-0.160
- ESTROGEN_RESPONSE_EARLY-0.130
- FATTY_ACID_METABOLISM-0.130
- KRAS_SIGNALING_DN-0.130
- CHOLESTEROL_HOMEOSTASIS-0.120
- NOTCH_SIGNALING-0.110
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MNG766 | — | — | 0.880 |
| 2 | TCGA-CR-7373-01A-11R-2016-07 | — | — | 0.879 |
| 3 | TCGA-A8-A07U-01A-11R-A034-07 | — | D | 0.853 |
| 4 | C3L-04071 | — | cohortSQ1 | 0.847 |
| 5 | SRR27320692 | — | — | 0.837 |
| 6 | MNG814 | — | — | 0.831 |
| 7 | TCGA-AR-A1AJ-01A-21R-A12P-07 | — | D | 0.829 |
| 8 | TCGA-XF-A8HE-01A-11R-A36F-07 | — | — | 0.827 |
| 9 | TCGA-AR-A1AT-01A-11R-A12P-07 | — | C | 0.827 |
| 10 | ERR2208915 | — | — | 0.826 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 32 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.610 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.590 | Idelalisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.560 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.500 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.490 | Idelalisib | — uncovered |
| COMPLEMENT | 0.430 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.410 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.340 | Idelalisib | — uncovered |
| G2M_CHECKPOINT | 0.320 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.300 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.290 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.290 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.280 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.270 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.220 | Inavolisib | — uncovered |
| APOPTOSIS | 0.200 | Idelalisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.200 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.190 | Temsirolimus | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.190 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.180 | Inavolisib | — uncovered |